Sangamo Therapeutics Inc. (NASDAQ:SGMO) saw a downside of -0.91% to close Tuesday at $8.71 after subtracting -$0.08 on the day. The 5-day average trading volume is 732,580 shares of the company’s common stock. It has gained $9.14 in the past week. An average of 881,945 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 887,058.
SGMO’s 1-month performance is -8.51% or -$0.95 on its low of $8.60 reached on 10/06/21. The company’s shares have touched a 52-week low of $8.60 and high of $19.43, with the stock’s rally to the 52-week high happening on 01/08/21. YTD, SGMO has lost -44.18% or -$6.89. However, the current price is down -55.17%% from the 52-week high price.
A Backdoor Way To Profit From Today’s Crypto Bull Market
In any crypto bull market, there's a lot of money to be made.
But what if we told you the best opportunities are not cryptocurrencies themselves… but instead, simply crypto stocks?
This strategy is simply and ridiculously easy.
Here are 6 ways to gain exposure to crypto outside the norm. This is arguably the safest bet you can make.
On Mar 23, 204 days have gone by since the last insider trading activity for Sangamo Therapeutics Inc. (SGMO). LOEB GARY (EVP, General Counsel & Sec.) most recently sold 17,524 shares at $13.13 per share on Mar 23. This transaction cost the insider $230,042. EVP, Technical Operations, Ramelmeier Rolf Andrew, sold 2,464 shares at a price of $16.74 on Dec 31. Then, on Dec 24, EVP, Technical Operations Ramelmeier Rolf Andrew sold 3,331 shares at a price of $18.13 per share. This transaction amounted to $60,391.
Sangamo Therapeutics Inc. (SGMO) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.19 for the sector.SGMO stock has a beta of 1.60. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 9.29 while the price-to-book (PB) in the most recent quarter is 2.82.
Sangamo Therapeutics Inc.’s quick ratio for the period ended June 29 was 4.00, with the current ratio over the same period at 4.00 meaning that SGMO stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.00, while the total debt to equity was 0.00The trailing 12-month EBITDA margin is -104.80%. The firm’s gross profit as reported stood at $247.74 million against revenue of $118.19 million.
For the quarterly period ending June 29 this year, Sangamo Therapeutics Inc.’s cash and short-term investments amounted to $359.78 million against total debt of $41.29 million. Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected SGMO to announce -$0.31 per share in earnings in its latest quarter, but it posted -$0.33, representing a -6.50% surprise. EBITDA for the quarter stood at more than -$43.5 million. SGMO stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 389.91 million, with total debt at $41.29 million. Shareholders hold equity totaling $145.34 million
Let’s look briefly at Sangamo Therapeutics Inc. (SGMO) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 12 October was 35.55% to suggest the stock is trending Neutral, with historical volatility in this time period at 32.48%.
The stock’s 5-day moving average is $8.77, reflecting a -1.58% or -$0.14 change from its current price. SGMO is currently trading -4.70% above its 20-day SMA, -20.38% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -9.55% and -51.09% respectively.
Stochastic %K and %D was 12.24% and 14.24% and the average true range (ATR) pointed at 0.35. The RSI (14) points at 38.30%, while the 14-day stochastic is at 8.59% with the period’s ATR at 0.36. The stock’s 9-day MACD Oscillator is pointing at -0.11 and -0.36 on the 14-day charts.
In the most recent analyst report for Sangamo Therapeutics Inc. (NASDAQ: SGMO), RBC Capital Mkts launched coverage with an Outperform rating. Analysts offering their rating for SGMO stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate SGMO as a “sell,”, while 2 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 1 rates the stock as overweight while 7 have offered a “buy” rating.
What is SGMO’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $11.00 and a high of $30.00, with their median price target at $22.00. Looking at these predictions, the average price target given by analysts is for Sangamo Therapeutics Inc. (SGMO) stock is $20.67.